Back

The safety and efficacy of treprostinil for the treatment of pulmonary arterial hypertension: a systematic review and meta-analysis of randomized controlled trials

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Current pharmacological treatments for pulmonary hypertension Pulmonary Hypertension ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Mr Hasan Khasawneh

Yarmouk University, Irbid (Jordan)

8 More presentations in this session

Presentation thumbnail
Effects of beta blockers on outcome in patients with PAH with and without comorbid conditions: a Multicenter Prospective Cohort Study (BNP-PL).
Doctor M. Waligora (Krakow, PL)
Abstract Slides Video
Presentation thumbnail
Combined ARNI and SGLT2i impacts on peak tricuspid regurgitant velocity and echocardiographic probability of pulmonary hypertension
Doctor M. Stracqualursi (Milan, IT)
Abstract Slides Video
Presentation thumbnail
Efficacy and tolerability of triple sequential combination therapies with selexipag in patients with pulmonary arterial hypertension : insights from a single-centre study
Doctor H. Tokgoz (Istanbul, TR)
Abstract Slides Video
Presentation thumbnail
Metoprolol therapy in patients with Eisenmenger syndrome (MINES) study. A single-centre, double-blinded, randomised, placebo-controlled trial
Doctor A. Pius (New Delhi, IN)
Abstract Slides Video
Presentation thumbnail
Efficacy of specific drug class therapy in pulmonary arterial hypertension associated with HIV, portal hypertension or both: a single Center experience
Doctor F. Cennerazzo (Bologna, IT)
Abstract Slides Video

Access the full session

Session thumbnail
Current pharmacological treatments for pulmonary hypertension

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Dramatic differences resulting from treatment timing of treprostinil in high-risk patients: a real-world data analysis
thumbnail
Congress Presentation
Comparison of triple oral and triple parenteral combination therapy in pulmonary arterial hypertension
thumbnail
Congress Presentation
Efficacy and tolerability of triple sequential combination therapies with selexipag in patients with pulmonary arterial hypertension : insights from a single-centre study

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources